Clinical Trial Update: Single-Centre Study of VR040(Inhaled Apomorphine) in Idiopathic Parkinson's Disease [Phase 2]

View source ↗

Summary

A Phase 2 single-centre trial evaluating VR040, an inhaled form of apomorphine, in idiopathic Parkinson's disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• VR040 (inhaled apomorphine) (apomorphine)

Snippet

Sponsor: South Glasgow University Hospitals NHS Trust | Conditions: Parkinson's Disease | Phase 2 | Status: COMPLETED